Procept Biorobotics Corp
NASDAQ:PRCT
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
27.89
74.69
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
P
|
Procept Biorobotics Corp
NASDAQ:PRCT
|
1.7B USD |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
211.7B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
191.8B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
139.1B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
130.5B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
124B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
59.1B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
49.5B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
57.2B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
49B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
37.6B USD |
Loading...
|
Market Distribution
| Min | -4 418 600% |
| 30th Percentile | -9.6% |
| Median | 3.1% |
| 70th Percentile | 11.3% |
| Max | 1 135 400% |
Other Profitability Ratios
Procept Biorobotics Corp
Glance View
Procept Biorobotics Corp. is a pioneering force in the medical technology landscape, blending innovative engineering with clinical insights to address some of the most pressing challenges in urology. Founded with a vision to revolutionize surgical care, the company developed the AquaBeam Robotic System, an advanced medical platform that leverages robotic precision and real-time ultrasound imaging. This system is primarily employed in performing Aquablation therapy, a minimally invasive treatment designed to alleviate symptoms of benign prostatic hyperplasia (BPH). By integrating robotics and imaging, Procept offers a solution that enhances the accuracy of prostate tissue removal while minimizing risks and downtime for patients—a significant advancement over conventional methods. Revenue generation for Procept Biorobotics centers on the sales of their AquaBeam systems, along with consumables and service contracts that provide ongoing support and upgrades for their hospital and clinical partners. Recognizing the critical nature of procedure efficiency and safety, the company also invests in broadening the application of its technology and frequently seeks endorsements through clinical trials and studies to validate their innovations. By ensuring their cutting-edge solutions meet the stringent demands of healthcare professionals and patients alike, Procept maintains a competitive edge, fostering both adoption and trust within the healthcare community while steadily driving their growth and financial success.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Procept Biorobotics Corp is -28.2%, which is above its 3-year median of -67.9%.
Over the last 3 years, Procept Biorobotics Corp’s Net Margin has increased from -126% to -28.2%. During this period, it reached a low of -126% on Sep 30, 2022 and a high of -28.2% on Sep 30, 2025.